Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcoma
Skin Cancers
Thyroid Cancers
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
The Journal of Targeted Therapies in Cancer
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
2013
|
2012
February 2019
August 2018
2018 June
2018 April
2018 February
2017 December
2017 October
2017 August
2017 June
2017 April
2017 February
2016 December
2016 October
2016 August
2016 June
2016 April
February 2016
December 2015
October 2015
August 2015
June 2015
April 2015
February 2015
December 2014
October 2014
August 2014
June 2014
April 2014
February 2014
December 2013
October 2013
August 2013
April 2013
February 2013
June 2013
November 2012
September 2012
June 2012
March 2012
JTT Articles
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
Researchers Look to CAR T-Cell Therapy as Immunotherapy Outcomes Diminish in Glioblastoma
>> View Peer-Reviewed Articles
Most Popular
Pembrolizumab Approved by FDA for Stage III Melanoma
Encouraging Activity Seen With Pembrolizumab in Non-Clear Cell RCC
Not Always Imperative to Change Drug Class After Disease Progression, Myeloma Expert Says
Ibrutinib and Palbociclib Combination Active in Previously Treated MCL